loading page

Diagnostic value of NPTX2 (neuronal pentraxin II) methylation in patients with pancreatic cancer: meta-analysis
  • +3
  • wenqi huang,
  • lifeng xue,
  • haoming xu,
  • jing xu,
  • hailan zhao,
  • quqiang nie
wenqi huang
Author Profile
lifeng xue
Author Profile
haoming xu
Author Profile
hailan zhao
Author Profile
quqiang nie
Author Profile


Purpose: Pancreatic cancer (PC) is a devasting disease of which mortality almost parallels its incidence. Pancreatic cancer tissue may express aberrantly methylated NPTX2, but it is unclear what the consequences of this are. The purpose of the present study was to assess the diagnostic performance of methylated NPTX2 in PC diagnosis. Methods: We conducted a comprehensive search of PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and the Cochrane Library for published studies from inception to July 15, 2020. Using STATA 13.0, diagnostic OR (DOR) and AUC (Area Under the Curve of Receiver Operating Characteristic) were calculated to evaluate the diagnostic efficacy. Results: Nine studies were found eligible for the meta-analysis. The overall results of DOR and AUC were 11 (95%CI: 4-26) and 0.80, respectively. These data indicate that aberrantly methylated NPTX2 can correctly predict PC. Subgroup analysis revealed that quantitative real-time methylation-specific PCR (QMSP) had the highest diagnostic value for differentiating pancreatic cancer from chronic pancreatitis using a laboratory method. Furthermore, the detection of hypermethylated NPTX2 found in plasma was suggested to be a promising diagnostic biomarker, though a meta-analysis was not feasible due to the limited number of samples. The Deeks’ funnel map revealed no obvious public bias in the literature. Conclusion: aberrantly methylated NPTX2 has high sensitivity and specificity for the diagnosis of pancreatic cancer. However, further research is required to validate the use of methylated NPTX2 as a biomarker in the clinical diagnosis of pancreatic cancer.

Peer review status:Published

15 Sep 2020Submitted to International Journal of Clinical Practice
15 Sep 2020Submission Checks Completed
15 Sep 2020Assigned to Editor
17 Sep 2020Reviewer(s) Assigned
12 Oct 2020Review(s) Completed, Editorial Evaluation Pending
29 Nov 20201st Revision Received
01 Dec 2020Submission Checks Completed
01 Dec 2020Assigned to Editor
01 Dec 2020Reviewer(s) Assigned
17 May 2021Review(s) Completed, Editorial Evaluation Pending
24 May 2021Editorial Decision: Accept
09 Jun 2021Published in International Journal of Clinical Practice. 10.1111/ijcp.14443